Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data ...

Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today ...

View Relmada Therapeutics Inc RLMD stock quote prices, financial information, real-time forecasts, and company news from CNN.

Detailed price information for Relmada Therapeutics Inc (RLMD-Q) from The Globe and Mail including charting and trades.

NDV-01 Phase 2 NMIBC results, Phase 3 mid-2026 outlook, competition, and $160m financing—read the full analysis.

Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on ...

The 12-month interim data from the ongoing Phase 2 trial showed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population. On Monday, the trial showed a ...

On Wednesday, Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced a preplanned interim analysis of the Reliance II Phase 3 study. Reliance II is designed to evaluate REL-1017 as an adjunctive treatment ...

The Phase 3 study was testing the Relmada drug, REL-1017, as a monotherapy. Patients were evaluated according to a rating scale that assesses the severity of depression symptoms—the higher the score, ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Relmada Therapeutics ( (RLMD)) just ...

Dec 9 (Reuters) - Relmada Therapeutics (RLMD.O), opens new tab said on Monday it would discontinue the two late-stage studies planned for the development of its depression drug and explore strategic ...

Relmada Therapeutics reported positive results from a human abuse potential trial with its lead candidate, REL-1017. REL-1017 is a bit controversial because it's a purified isomer of methadone, a ...